About half of heart failure cases are preserved ejection fraction cases, and more than 80 percent of patients with this heart failure are obese or overweight, according to Novo Nordisk. The condition is associated with symptoms and physical limitations affecting daily life, such as fatigue, shortness of breath, reduced ability to exercise and swelling.
After 52 weeks of taking Wegovy (semaglutide) 2.4 milligrams, adults in the study reported 13.3 percent weight loss, and they noted a 16.6-point increase in improvement on their symptoms and physical limitations. The measurement was captured with the patient-reported Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.
Patients taking the placebo saw an 8.7-point increase.
Novo Nordisk said it plans to file for a broader drug approval label in early 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
